Lee Pitcher MP: written questions

Lee Pitcher MP: full overview

4 Jul 2025–3 Jul 2026

How these years work

Our reporting years run from 4 July to 3 July, starting with the 2024 general election. They are not official parliamentary sessions. Office costs keep IPSA’s April–March financial years. Records may cover only part of a year; a missing record does not mean no work was done.

Compare reporting years, sessions and IPSA financial years.

Written questions: dates and coverage

Source checked
21 Nov 2026
Last successful import
21 Nov 2026
Records dated through
20 Nov 2026
Selected period
Reporting year 2: 4 Jul 2025 to 3 Jul 2026
Completeness
Published snapshot: 25,747 records in the source window 23 Aug 2026 to 21 Nov 2026. The published snapshot covers its stated source window. Answers and corrections can appear later; no indexed answer does not prove that none exists.

How to read these datesOfficial source

Understand written questions, dates and answers.

Read what this MP said, asked and contributed in Parliament.

39 published records · newest first.

Written questions

  • Sodium Valproate and Surgical Mesh Implants: CompensationDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15255More

    Question: To ask the Secretary of State for Health and Social Care, if he will ensure that the Government provides, by 16 July 2026, the information requested by the Patient Safety Commissioner on (a) action taken in response to the Hughes Report, (b) outstanding s

    Answer: The Patient Safety Commissioner wrote to the Prime Minister on 16 June, requesting information regarding internal and cross-Government discussions in relation to the Hughes Report, actions that have been taken beyond the Department, and the future plans r...

    Answered 6 Jul 2026

    Original Parliament record
  • Migraines: EmploymentDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15253More

    Question: To ask the Secretary of State for Health and Social Care, whether he plans to collect or publish data on the number of people whose work capability is affected by migraine or related headache disorders.

    Answer: The Office for National Statistics collects information on health conditions through the Labour Force Survey (LFS), which is based on interviews with people resident in households in the United Kingdom. The LFS covers this in two relevant ways. It asks re...

    Answered 15 Jul 2026

    Original Parliament record
  • Migraines: EmploymentDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15252More

    Question: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage employers to provide reasonable workplace support for employees affected by migraine.

    Answer: The Government is committed to working collaboratively to support disabled people and people with health conditions, including people affected by migraine. The Department of Health and Social Care and the Department for Work and Pensions’ Joint Work and H...

    Answered 10 Jul 2026

    Original Parliament record
  • Migraines: EmploymentDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15251More

    Question: To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the Secretary of State for Health and Social Care on cross-government support for people whose ability to work is affected by migraine.

    Answer: The Government is committed to working collaboratively to support disabled people and people with health conditions, including people affected by migraine. The Department of Health and Social Care and the Department for Work and Pensions’ Joint Work and H...

    Answered 10 Jul 2026

    Original Parliament record
  • Migraines: EmploymentDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15250More

    Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of migraine on levels of employment, absenteeism and economic inactivity in sufferers.

    Answer: No assessment has been made of the potential impact of migraine on employment and economic inactivity. This information isn’t available as the Labour Force Survey (LFS), the primary source for data on labour market participation and economic inactivity, o...

    Answered 16 Jul 2026

    Original Parliament record
  • Migraines: Health ServicesDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15249More

    Question: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that patients can access the most effective innovations for migraine.

    Answer: The National Institute for Health and Care Excellence (NICE) has recommended several new medicines as options for the treatment of migraine. The National Health Service in England is legally required to fund medicines recommended in a NICE appraisal, usua...

    Answered 8 Jul 2026

    Original Parliament record
  • Migraines: Health ServicesDepartment of Health and Social CareTabled 1 Jul 2026AnsweredUIN 15248More

    Question: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve outcomes for people living with migraine.

    Answer: The Government recognises the significant impact that migraine can have on individuals’ quality of life and is committed to improving care and outcomes for people living with this condition.NHS England is supporting improvements in migraine care through n...

    Answered 10 Jul 2026

    Original Parliament record
  • Disability: ChildrenDepartment of Health and Social CareTabled 30 Jun 2026AnsweredUIN 14747More

    Question: To ask the Secretary of State for Health and Social Care, what guidance his Department provides to NHS and local authority professionals on responsibility for commissioning specialist night-time safety equipment for children with complex developmental dis

    Answer: The Children and Families Act 2014 requires that education, health, and social care services must work together to meet the needs of children and young people with special educational needs and disabilities (SEND). Integrated care boards (ICBs) are respon...

    Answered 17 Jul 2026

    Original Parliament record
  • Breasts: Plastic SurgeryDepartment of Health and Social CareTabled 16 Jun 2026AnsweredUIN 10443More

    Question: To ask the Secretary of State for Health and Social Care, whether his Department plans to commission updated research into the long-term health effects of Poly Implant Prothèse breast implants on women.

    Answer: The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research into long-term health effects of Poly Implant Prothèse breast (PIP) implants but welcomes fundi...

    Answered 30 Jun 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9219More

    Question: To ask the Secretary of State for Health and Social Care, what information his Department holds on (a) the likelihood of patients who develop one dopamine agonist-associated impulse control disorder developing additional impulse control disorders and (b)

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9217More

    Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome alone, compared with patients with restless legs syndrome and attention deficit hyperactivity disorder, auti

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9216More

    Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome treated with dopamine agonists who have co-existing neurodevelopmental or psychiatric diagnoses, including a

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9215More

    Question: To ask the Secretary of State for Health and Social Care, what assessment the Department has made of risk factors for dopamine agonist-induced impulse control disorders, including age, renal impairment, duration of exposure, cumulative dose, polypharmacy,

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9214More

    Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on the average age at (a) initiation of dopamine agonist therapy, (b) first report or diagnosis of an impulse control disorder while taking a dopamine agonist and (c)

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9213More

    Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the average length of time patients remain on dopamine agonists or partial dopamine agonists for each licensed indication, (b) the proportion of patients who r

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9212More

    Question: To ask the Secretary of State for Health and Social Care, what information national pharmacovigilance systems and clinical datasets provide on the range and relative frequency of withdrawal symptoms associated with dopamine agonist discontinuation, includ

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9211More

    Question: To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or first report of impulse control disorder symptoms and (

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9210More

    Question: To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the number and proportion of patients who develop impulse control disorders while taking dopamine agonists and subsequently (a) continue dopamine agonis

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9209More

    Question: To ask the Secretary of State for Health and Social Care, what data national bodies hold on (a) the number and proportion of people prescribed dopamine agonists who self-report impulse control disorders and (b) the number and proportion whose impulse cont

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9208More

    Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the use of artificial intelligence and digital tools within the NHS and the Medicines and Healthcare products Regulatory Agency to (a) detect potential do

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9207More

    Question: To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the effectiveness of how dopamine agonist-related impulse control disorders and augmentation are taught and assessed in undergraduate medical educat

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9206More

    Question: To ask the Secretary of State for Health and Social Care, whether his Department holds audit or research data on differences between neurology or movement disorder specialists and general practitioners in (a) warning patients and families about dopamine a

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9205More

    Question: To ask the Secretary of State for Health and Social Care, what guidance is issued to clinicians on discussing in advance with patients, and where appropriate their families, how treatment should be managed if severe impulse control disorders develop while

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9204More

    Question: To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the levels of (a) sexually transmitted infections acquired in the context of dopamine agonist-induced hypersexuality and (b) unplanned pregnancies among w

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
  • Drugs: Side EffectsDepartment of Health and Social CareTabled 11 Jun 2026AnsweredUIN 9203More

    Question: To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices whe

    Answer: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...

    Answered 8 Jul 2026

    Original Parliament record
Explore activity by topic or department

Written questions by answering department

4 Jul 2025–3 Jul 2026. One record per UIN and tabled date; the named department is not a measure of answer quality.

View as listCabinet Office: 1Cabinet Office1Department for Business and Trade: 1Department for Business and Trade1Department for Culture, Media and Sport: 3Department for Culture, Media a…3Department for Education: 2Department for Education2Department for Energy Security and Net Zero: 1Department for Energy Security …1Department for Environment, Food and Rural Affairs: 1Department for Environment, Foo…1Department for Science, Innovation and Technology: 3Department for Science, Innovat…3Department for Transport: 6Department for Transport6Department for Work and Pensions: 3Department for Work and Pensions3Department of Health and Social Care: 39Department of Health and Social…39Home Office: 3Home Office3Ministry of Defence: 1Ministry of Defence1Ministry of Housing, Communities and Local Government: 8Ministry of Housing, Communitie…8Ministry of Justice: 3Ministry of Justice3Treasury: 4Treasury4
What this shows and doesn't show
4 Jul 2025–3 Jul 2026. One record per UIN and tabled date; the named department is not a measure of answer quality. Published records do not measure effort or effectiveness. Methodology.
Department or topicPublished records
Cabinet Office1
Department for Business and Trade1
Department for Culture, Media and Sport3
Department for Education2
Department for Energy Security and Net Zero1
Department for Environment, Food and Rural Affairs1
Department for Science, Innovation and Technology3
Department for Transport6
Department for Work and Pensions3
Department of Health and Social Care39
Home Office3
Ministry of Defence1
Ministry of Housing, Communities and Local Government8
Ministry of Justice3
Treasury4

Published records only — not a full account of an MP’s work. How we work →